Bio-Rad Laboratories, Inc. (BIO)
NYSE · Healthcare · Medical Devices
$379.82+2.89%as of Oct 6, 2026, 1:35 AM ET
- Market cap
- $10.2B
- P/E (trailing)
- 48.1
- Forward P/E
- 38.3
- 52-week range
- $236.73 – $396.23
- 52-week change
- +24.49%
- EPS (trailing)
- $7.89
- Analyst rating
- 3.0 Hold
- Next earnings
- Oct 29, 2026
Fiscal year to Dec 2025
- Revenue
- $2.6B (+0.65%)
- Net income
- $760M
- Operating margin
- 1.8%
- Diluted EPS
- $27.85
- Free cash flow
- $375M
From the company’s annual report on SEC EDGAR.
About Bio-Rad Laboratories, Inc.
Bio-Rad Laboratories, Inc. develops, manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, Latin America, and internationally. It operates through two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantify biological materials, including cells, proteins, and nucleic acids used in research and biopharmaceutical laboratory environments, as well as for biopharmaceutical manufacturing, quality control process, food safety, and science education applications. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology companies, food producers, and testing laboratories. Its Clinical Diagnostics segment designs, manufactures, markets, and supports diagnostic test systems, informatics systems, test kits, and specialized quality controls for clinical, hospital, diagnostic reference, and transfusion and physician office laboratories, as well as software.
Headquarters: Hercules, United States · 7,450 employees · bio-rad.com